{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:17:12Z","timestamp":1783343832488,"version":"3.54.6"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum der Ruhr-Universit\u00e4t Bochum"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate-specific membrane antigen-direct radioligand therapy (PSMA RLT) is primarily used to treat castration-resistant metastatic prostate cancer (PCa) after prior treatment options have been exhausted. Occasionally, other tumor entities, such as parotid carcinoma in this case, also express prostate-specific membrane antigen (PSMA) on their cell surface.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case description<\/jats:title>\n                    <jats:p>We present the case of a white 67-year-old patient newly diagnosed with locally advanced PCa despite multiple cycles of Lutetium-177-labeled prostate-specific membrane antigen radioligand therapy ([177Lu]Lu-PSMA-RLT), which he had received for metastatic parotid carcinoma. Interestingly, no regressive histopathological changes were found in the prostate biopsy specimen, despite given PSMA-expression in the prostate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The potential selection of high-grade disease, which appears to have occurred in this patient, underscores the need for further large-scale histopathological examination and thorough follow-up of the current investigational approaches using [177Lu]Lu-PSMA-RLT in high-risk prostate cancer (PCa).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-026-06225-2","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:29:48Z","timestamp":1783340988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Newly diagnosed high-risk localized prostate cancer after multiple [177Lu]Lu-PSMA radioligand therapy in the context of metastatic parotid carcinoma: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2198-2730","authenticated-orcid":false,"given":"Christopher","family":"Orf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Analena Elisa","family":"Handke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Noldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Roghmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Dellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl H.","family":"Tully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"1","key":"6225_CR1","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res Off J Am Assoc Cancer Res. 1997;3(1):81\u20135.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"11","key":"6225_CR2","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","volume":"82","author":"DG Bostwick","year":"1998","unstructured":"Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82(11):2256\u201361.","journal-title":"Cancer"},{"issue":"1","key":"6225_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/MOU.0000000000000685","volume":"30","author":"IO Lawal","year":"2020","unstructured":"Lawal IO, Bruchertseifer F, Vorster M, Morgenstern A, Sathekge MM. Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer. Curr Opin Urol. 2020;30(1):98\u2013105.","journal-title":"Curr Opin Urol"},{"key":"6225_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.biopha.2016.12.083","volume":"87","author":"CA de Ferreira","year":"2017","unstructured":"de Ferreira CA, Fuscaldi LL, Townsend DM, Rubello D, de Barros ALB. Radiolabeled bombesin derivatives for preclinical oncological imaging. Biomed Pharmacother Biomedecine Pharmacother. 2017;87:58\u201372.","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"issue":"8","key":"6225_CR5","first-page":"1169","volume":"56","author":"M Weineisen","year":"2015","unstructured":"Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-Labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med Off Publ Soc Nucl Med. 2015;56(8):1169\u201376.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"3","key":"6225_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2967\/jnmt.122.263814","volume":"50","author":"EE Parent","year":"2022","unstructured":"Parent EE, Savir-Baruch B, Gayed IW, Almaguel F, Chin BB, Pantel AR, et al. 177Lu-PSMA therapy. J Nucl Med Technol. 2022;50(3):205\u201312.","journal-title":"J Nucl Med Technol"},{"issue":"11","key":"6225_CR7","doi-asserted-by":"publisher","first-page":"12477","DOI":"10.18632\/oncotarget.7245","volume":"7","author":"H Ahmadzadehfar","year":"2016","unstructured":"Ahmadzadehfar H, Eppard E, K\u00fcrpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7(11):12477\u201388.","journal-title":"Oncotarget"},{"issue":"10","key":"6225_CR8","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.21037\/tau-20-1135","volume":"10","author":"L Lunger","year":"2021","unstructured":"Lunger L, Tauber R, Feuerecker B, Gschwend JE, Eiber M, Heck MM. Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer. Transl Androl Urol. 2021;10(10):3963\u201371.","journal-title":"Transl Androl Urol"},{"issue":"3","key":"6225_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","volume":"85","author":"RS Eapen","year":"2024","unstructured":"Eapen RS, Buteau JP, Jackson P, Mitchell C, Oon SF, Alghazo O, et al. Administering [(177)Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1\/2 study. Eur Urol. 2024;85(3):217\u201326.","journal-title":"Eur Urol"},{"issue":"2","key":"6225_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.euo.2022.09.002","volume":"6","author":"S Golan","year":"2023","unstructured":"Golan S, Frumer M, Zohar Y, Rosenbaum E, Yakimov M, Kedar D, et al. Neoadjuvant (177)Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: a single-arm phase 1 trial. Eur Urol Oncol. 2023;6(2):151\u20139.","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"6225_CR11","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1007\/s00259-025-07083-8","volume":"52","author":"R Laudicella","year":"2025","unstructured":"Laudicella R, Bauckneht M, Burger IA, Cacciola A, Fanti S, Farolfi A, et al. The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52(7):2723\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"6225_CR12","first-page":"1786","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Stuparu AD, Evans-Axelsson S, L\u00fcckerath K, Wei L, Kim W, et al. Establishing (177)Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer. J Nucl Med Off Publ Soc Nucl Med. 2017;58(11):1786\u201392.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"9","key":"6225_CR13","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, et al. Joint EANM\/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50(9):2830\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"6225_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2214\/AJR.18.20845","volume":"213","author":"MP Yadav","year":"2019","unstructured":"Yadav MP, Ballal S, Sahoo RK, Dwivedi SN, Bal C. Radioligand therapy with (177)Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2019;213(2):275\u201385.","journal-title":"AJR Am J Roentgenol"},{"issue":"12","key":"6225_CR15","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.7150\/thno.96322","volume":"14","author":"PHJ Slootbeek","year":"2024","unstructured":"Slootbeek PHJ, Luna-Velez MV, Priv\u00e9 BM, van der Doelen MJ, Kloots ISH, Pamidimarri Naga S, et al. Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 2024;14(12):4555\u201369.","journal-title":"Theranostics"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06225-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06225-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06225-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:29:49Z","timestamp":1783340989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-06225-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6225"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06225-2","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In compliance with the Ethics Committee of the German Medical Association of Westphalia-Lippe, ethical approval and consent to participate was not required for this study as it represents a retrospective single case analysis of previously collected and fully anonymized data encountered during clinical practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of this case report and any accompanying images was obtained from the patient\u2019s next of kin. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"372"}}